TSXV - Delayed Quote CAD

Kane Biotech Inc. (KNE.V)

Compare
0.1300 -0.0050 (-3.70%)
At close: October 18 at 1:12 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.
NameTitlePayExercisedYear Born
Mr. Marc Edwards President, CEO & Director 268.5k -- --
Mr. Ray Dupuis Chief Financial Officer 161.69k -- --
Dr. Robert B. Huizinga CNeph(C), M.Sc., MSc(Epi), Ph.D., R.N., RN NNC Executive Chairman & Member of Scientific Advisory Board -- -- 1965
Dr. Gregory S. Schultz Ph.D. Chief Scientific Officer & Member of Scientific Advisory Board -- -- 1950
Lorne Gorber Investor Relations -- -- --
Ms. Wendy Nachtigall Director of Marketing -- -- --
Ms. Lori Christofalos Chief Quality Officer -- -- --
Nicole Sendey Investor Relations Adviser -- -- --

Kane Biotech Inc.

100 Innovation Drive
Suite 290
Winnipeg, MB R3T 6G2
Canada
204-453-1301 https://kanebiotech.com
Sector:?
Healthcare
Industry:?
Biotechnology

Description

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. The company is also developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; coactiv+ Antimicrobial Wound Rinse for use in acute and chronic wounds; coactiv+ Antimicrobial Wound Gel Spray for use in acute, chronic wounds, and first and second degree burns; and DispersinB Hydrogel for prosthetic joint infection. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

Corporate Governance

Kane Biotech Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 26, 2024 at 10:59 AM UTC - December 2, 2024 at 12:00 PM UTC

Kane Biotech Inc. Earnings Date

Recent Events

March 13, 2017 at 12:00 AM UTC

Dividend Date

Related Tickers